Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Insulin Biosimilars Companies

Insulin biosimilars are biologic drugs that are highly similar to existing insulin products. They are designed to be interchangeable with the reference insulin products while providing more affordable options for patients.

Insulin Biosimilars Key Companies

Latest Insulin Biosimilars Companies Update:

Eli Lilly and Company (US) launches Rezvoglar (insulin glargine-aglr), its interchangeable biosimilar to Lantus, at a 78% discount to the list price of the originator brand.

Biocon Biosimilar Solutions (India) announces a 106% year-over-year increase in sales for its biosimilar portfolio, attributing the growth to market share gains in the US and EU

Teva Pharmaceutical Industries Ltd. (Israel) files a Biologics License Application (BLA) with the US FDA for its long-acting insulin glargine biosimilar, marking its entry into the US insulin biosimilar market.

Mylan Pharmaceutical Inc. (US) and Sanofi S.A. (France) partner to develop and commercialize two interchangeable biosimilars for Novolog and Levemir, targeting the US insulin market.

The European Medicines Agency (EMA) approves Civica Rx’s Semglee biosimilar (insulin glargine-yfgn) for use in the EU, expanding access to this affordable insulin option.

List of Insulin Biosimilars Key companies in the market

Sanofi S.A.

Boehringer Ingelheim

Eli Lilly & Co.

Novo Nordisk A/S

Biocon

Merck & Co.

Mylan N.V.

Sandoz

Fresenius Kabi

Amgen

Insulin Biosimilars Market Highlights:

Insulin Biosimilars Market Size

Insulin Biosimilars Market Trends

Insulin Biosimilars Market Analysis

Insulin Biosimilars Market Share

Insulin Biosimilars Market Highlights:

Insulin Biosimilars Market Trends

Insulin Biosimilars Market Analysis

Insulin Biosimilars Market Share

Insulin Biosimilars Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.